Overview

Photodynamic Therapy Using Topical Aminolevulinic Acid in Treating Patients With Actinic Keratosis

Status:
Terminated
Trial end date:
2009-05-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, abnormal cells are killed. Photodynamic therapy using topical aminolevulinic acid may be effective against actinic keratosis. PURPOSE: This randomized clinical trial is studying how well different photodynamic therapy regimens using topical aminolevulinic acid work in treating patients with actinic keratosis.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Roswell Park Cancer Institute
Collaborator:
National Cancer Institute (NCI)
Treatments:
Aminolevulinic Acid
Criteria
DISEASE CHARACTERISTICS:

- Actinic keratosis lesion located in any of the following body sites:

- Stratum 1*: face and neck, scalp, or upper torso

- At least 1 clinically evident thin actinic keratosis on each side of the
midline of any of the above areas

- Stratum 2*: arms or legs

- At least 1 clinically evident thick actinic keratosis on each arm or leg
NOTE: *One patient may be in one or both strata depending on the location of
the lesion(s)

- Lesions to be treated on this protocol must not have been previously treated by other
modalities for at least 2 months prior to study entry

PATIENT CHARACTERISTICS:

- No porphyria or known hypersensitivity to porphyrins

- No known photosensitivity disease

- No known sensitivity to any components of aminolevulinic acid topical solution

- Not pregnant or nursing

PRIOR CONCURRENT THERAPY:

- Other concurrent topical therapies at lesion sites other than those used in this
protocol are allowed

- No other concurrent photosensitizer drugs